Upstaging of urothelial cancer at the time of radical cystectomy: Factors associated with upstaging and its effect on outcome

BJU International

Volumn 110, Issue 6, 2012, Pages 804-811

  Turker, Polat ^a,e   Bostrom, Peter J ^a,c   Wroclawski, Marcelo L ^a   Van Rhijn, Bas ^a   Kortekangas, Hannes ^c   Kuk, Cynthia ^a,b   Mirtti, Tuomas ^d   Fleshner, Neil E ^a   Jewett, Michael A ^a   Finelli, Antonio ^a   Kwast, Theo Vander ^a   Evans, Andy ^a   Sweet, Joan ^a   Laato, Matti ^c   Zlotta, Alexandre R ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TURKU   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e NAMIK KEMAL UNIVERSITY   (Turkey)

Author keywords

bladder cancer; radical cystectomy; upstaging

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER MUSCLE; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER UPSTAGING; CARCINOMA IN SITU; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84865471861     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.10939.x     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
2. Bostrom PJ, van Rhijn Bas WG, Fleshner N, et al,. Staging and staging errors in bladder cancer. Eur Urol Suppl 2010; 9: 7
3. Shariat SF, Palapattu GS, Karakiewicz PI, et al,. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51: 137-49; discussion 49-51
4. McLaughlin S, Shephard J, Wallen E, Maygarden S, Carson CC, Pruthi RS,. Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. Int Braz J Urol 2007; 33: 25-31; discussion -2
5. Svatek RS, Shariat SF, Novara G, et al,. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011; 107: 898-904
6. Guzzo TJ, Magheli A, Bivalacqua TJ, et al,. Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology 2009; 74: 1276-80
7. Grossman HB, Natale RB, Tangen CM, et al,. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-66
8. Clark PE,. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2009; 9: 821-30
9. Epstein JI, Amin MB, Reuter VR, Mostofi FK,. The world Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-48
10. Sobin DH, Wittekind CH, eds. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss, 2002: 199-202
11. Eble J, Sauter G, Epstein J, et al,. The World Health Organization Classification of Tumors of the Urinary System and Male Genital System. Lyon: IARC Press, 2004
12. Cheng L, Neumann RM, Weaver AL, et al,. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens. Am J Clin Pathol 2000; 113: 275-9
13. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA,. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170: 433-7
14. Divrik RT, Yildirim U, Zorlu F, Ozen H,. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006; 175: 1641-4
15. Zlotta AR, Fleshner NE, Jewett MA,. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 2009; 3: S199-205
16. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED,. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol 2007; 177: 1727-31
17. Herr HW,. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162: 74-6
18. Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B,. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003; 43: 241-5
19. Schwaibold HE, Sivalingam S, May F, Hartung R,. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006; 97: 1199-201
20. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361: 1927-34
21. Advanced Bladder Cancer Overview Collaberation. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005; (2): CD005246
22. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM,. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007; 178: 451-4
23. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202-5; discussion 5-6
24. Bolenz C, Herrmann E, Bastian PJ, et al,. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int 2010; 106: 493-9
25. Canter D, Guzzo T, Resnick M, et al,. The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis. BJU Int 2008; 102: 952-7
26. Lotan Y, Gupta A, Shariat SF, et al,. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005; 23: 6533-9
27. Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT,. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 2008; 180: 1928-32
28. Streeper NM, Simons CM, Konety BR, et al,. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int 2009; 103: 475-9
29. Resnick MJ, Bergey M, Magerfleisch L, Tomaszewski JE, Malkowicz SB, Guzzo TJ,. Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJU Int 2011; 107: 46-52
30. Lopez-Beltran A, Cheng L,. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol 2006; 37: 1371-88
31. Black PC, Brown GA, Dinney CP,. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2009; 27: 3-7
32. Honma I, Masumori N, Sato E, et al,. Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 2004; 64: 744-8